Chemomab Therapeutics (CMMB) Operating Expenses (2017 - 2026)

Chemomab Therapeutics (CMMB) has reported Operating Expenses for 10 consecutive years, with $2.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 0.93% year-over-year to $2.2 million; the trailing twelve-month figure through Jun 2026 stood at $7.9 million (down 37.59% YoY), and the FY2025 full-year result was $9.6 million, down 35.09% from the prior year.
• Operating Expenses grew to $2.2 million in Q2 2026 per CMMB's latest filing, from $1.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $9.0 million in Q1 2023 and bottomed at $1.8 million in Q3 2025.
• Historically, Operating Expenses has averaged $4.6 million across 5 years, with a median of $3.8 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses jumped 213.13% in 2022, then sank 55.47% in 2023.
• Over 5 years, Operating Expenses stood at $8.6 million in 2022, then sank by 55.47% to $3.8 million in 2023, then decreased by 16.5% to $3.2 million in 2024, then plunged by 38.56% to $2.0 million in 2025, then gained by 13.53% to $2.2 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $2.2 million, $1.8 million, and $2.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.